Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-432 adjuvant selpercatinib in RET fusion-positive NSCLC
CTR20212707Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jan 2022; status: active.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212707.